Panja Prasanta, Manne Upender, Awasthi Vibhudutta, Bhattacharya Resham, Mukherjee Priyabrata
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Cancer Lett. 2025 Mar 1;612:217454. doi: 10.1016/j.canlet.2025.217454. Epub 2025 Jan 11.
The tumor microenvironment (TME) plays a pivotal role in cancer progression by fostering intricate multicellular crosstalk among cancer cells, stromal cells, and immune cells. This review explores the emerging paradigm of utilizing nanoparticles to disrupt this crosstalk within the TME as a therapeutic strategy. Nanoparticles are engineered with precise physicochemical properties to target specific cell types and deliver therapeutic payloads, thereby inhibiting critical signaling pathways involved in tumor growth, invasion, and metastasis. The mechanisms involved include modulation of the immune response, interference with growth factor signaling, and induction of programmed cell death in cancer cells. Challenges such as biocompatibility, efficient delivery, and potential development of resistance are discussed alongside promising advancements in nanoparticle design. Moving forward, integration of nanoparticle-based therapies with existing treatment modalities holds great potential for enhancing therapeutic efficacy and personalized medicine in cancer therapy.
肿瘤微环境(TME)通过促进癌细胞、基质细胞和免疫细胞之间复杂的多细胞串扰,在癌症进展中发挥关键作用。本综述探讨了利用纳米颗粒破坏TME内这种串扰作为一种治疗策略的新兴模式。纳米颗粒经过精确的物理化学性质设计,以靶向特定细胞类型并递送治疗载荷,从而抑制参与肿瘤生长、侵袭和转移的关键信号通路。涉及的机制包括免疫反应的调节、生长因子信号传导的干扰以及癌细胞中程序性细胞死亡的诱导。在讨论诸如生物相容性、有效递送和耐药性潜在发展等挑战的同时,也介绍了纳米颗粒设计方面的有前景的进展。展望未来,基于纳米颗粒的疗法与现有治疗方式的整合在提高癌症治疗的疗效和个性化医疗方面具有巨大潜力。